Erratum: Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2014.168);Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond

JAMA Oncology

Volumn 1, Issue 1, 2015, Pages 23-32

  Hansford, Samantha ^a,b   Kaurah, Pardeep ^a,b   Li Chang, Hector ^a,b   Woo, Michelle ^a,b   Senz, Janine ^a,b   Pinheiro, Hugo ^c   Schrader, Kasmintan A ^a   Schaeffer, David F ^b   Shumansky, Karey ^a   Zogopoulos, George ^d,e   Santos, Teresa Almeida ^f,g   Claro, Isabel ^h   Carvalho, Joana ^c   Nielsen, Cydney ^a,b   Padilla, Sarah ^a   Lum, Amy ^a   Talhouk, Aline ^a,b   Baker Lange, Katie ⁱ   Richardson, Sue ^j   Lewis, Ivy ^k   Lindor, Noralane M ^l   Pennell, Erin ^m   MacMillan, Andree ^k   Fernandez, Bridget ^k   Keller, Gisella ⁿ   Lynch, Henry ^o   Shah, Sohrab P ^a   Guilford, Parry ^p   Gallinger, Steven ^q,r   Corso, Giovanni ^s,t   Roviello, Franco ^t,u   Caldas, Carlos ^j   Oliveira, Carla ^c,v   Pharoah, Paul D P ^w,x   Huntsman, David G ^a,b   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF PORTO   (Portugal)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^g UNIVERSITY OF COIMBRA   (Portugal)

^h INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

ⁱ PARK NICOLLET CLINIC   (United States)

^j CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^k Medical Genetics Program   (Canada)

^l MAYO CLINIC   (United States)

^m Eastern Health Canada   (Canada)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF OTAGO   (New Zealand)

^q UNIVERSITY OF TORONTO   (Canada)

^r MOUNT SINAI HOSPITAL   (Canada)

^s EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^t UNIVERSITY OF SIENA   (Italy)

^u UNIVERSITY HOSPITAL OF SIENA   (Italy)

^v University of Porto   (Portugal)

^w UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^x UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CDH1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CANADA; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HEREDITY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PEDIGREE; PENETRANCE; PHENOTYPE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; STOMACH NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CADHERINS; CANADA; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEREDITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PEDIGREE; PENETRANCE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84989787164     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0410     Document Type: Erratum

References (50)

1. International Agency for Research on Cancer. Globocan 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed October 13, 2013.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
3. Zanghieri G, Di Gregorio C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer. 1990;66(9):2047-2051.
4. La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer. 1992;70(1):50-55.
5. Fitzgerald RC, Hardwick R, Huntsman D, et al; International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research [correction published in J Med Genet. 2011;48(3):216]. J Med Genet. 2010;47(7):436-444.
6. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36(12):873-880.
7. Pharoah PD, Guilford P, Caldas C; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348-1353.
8. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297(21):2360-2372.
9. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904-1909.
10. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41(7):508-517.
11. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11(15):5401-5409.
12. Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18(9):1545-1555.
13. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol. 1988;5(6):471-472.
14. Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13(1):1-10.
15. Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer. 2012;12:8.
16. Forcet C, Etienne-Manneville S, Gaude H, et al. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum Mol Genet. 2005;14(10):1283-1292.
17. Yoon KA, Ku JL, Choi HS, et al. Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients. Br J Cancer. 2000;82(8):1403-1406.
18. Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261-268.
19. Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011;306(4):410-419.
20. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32(2):321-325.
21. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14(1):21-33.
22. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci. 2013;116:337-359.
23. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat. 2002;19(5):510-517.
24. Fujita H, Lennerz JK, Chung DC, et al. Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol. 2012;36(11):1709-1717.
25. Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245(6):873-879.
26. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130(4):612-617.
27. Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol. 2009;16(7):1890-1895.
28. Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery. 2011;149(3):347-355.
29. Majewski IJ, Kluijt I, Cats A, et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229(4):621-629.
30. Ferla R, Calò V, Cascio S, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007;18(suppl 6):vi93-vi98.
31. Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J.2010;1(3):397-412.
32. Lubinski J, Phelan CM, Ghadirian P, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3(1):1-10.
33. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700-710.
34. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubiński J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer. 2002;87(8):888-891.
35. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer.2012;11(2):235-242.
36. Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer. 1999;35(8):1248-1257.
37. Maier C, Vesovic Z, Bachmann N, et al. Germline mutations of the MSR1 gene in prostate cancer families from Germany. Hum Mutat. 2006;27(1):98-102.
38. Wang L, McDonnell SK, Cunningham JM, et al. No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet. 2003;35(2):128-129.
39. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65.
40. Goldgar DE, Healey S, Dowty JG, et al; BCFR; kConFab. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011;13(4):R73.
41. Stredrick DL, Garcia-Closas M, Pineda MA, et al. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Hum Mutat. 2006;27(6):538-544.
42. Rahman N, Seal S, Thompson D, et al; Breast Cancer Susceptibility Collaboration (UK). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165-167.
43. Erkko H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316-319.
44. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.
45. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497-506.
46. Le Maréchal C, Masson E, Chen JM, et al. Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet. 2006;38(12):1372-1374.
47. Felderbauer P, Schnekenburger J, Lebert R, et al. A novel A121T mutation in human cationic trypsinogen associated with hereditary pancreatitis: functional data indicating a loss-of-function mutation influencing the R122 trypsin cleavage site. J Med Genet. 2008;45(8):507-512.
48. Németh BC, Sahin-Tóth M. Human cationic trypsinogen (PRSS1) variants and chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014;306(6):G466-G473.
49. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
50. Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136(7):2137-2148.